Breast cancer, metastaticLBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.